Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimme Hyrich

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Pharmacogenomics|May 17, 2016
Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohortSamantha Louise Smith, Darren Plant, Xiu Hue Lee, et al.
Rheumatology (Oxford, England)|January 17, 2019
Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry dataSamuel Hawley, M Sanni Ali, René Cordtz, et al.
Pharmacogenetics and Genomics|March 20, 2010
Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment responseCatherine Potter, Laura J Gibbons, John D Bowes, et al.
Journal of Pediatric Psychology|April 23, 2025
The interplay between pain and disease activity: personal models of pain beliefs and emotional representations in children and young people with juvenile idiopathic arthritis in a UK nationwide prospective inception cohortDanielle C Mountain, Stephanie Shoop-Worrall, Lis Cordingley, et al.
Pharmacogenetics and Genomics|March 6, 2009
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patientsJohn D Bowes, Catherine Potter, Laura J Gibbons, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
The Pharmacogenomics Journal|September 1, 2018
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisJonathan Massey, Darren Plant, Kimme Hyrich, et al.
Rheumatology Advances in Practice|January 5, 2026
Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDsMichael Stadler, Shae Bindra, Annie Cheung, et al.
Rheumatology (Oxford, England)|June 30, 2020
Translating research into clinical practice: quality improvement to halve non-adherence to methotrexateAnne Barton, Meghna Jani, Christine Bundy, et al.
Rheumatology Advances in Practice|January 11, 2019
Prevalence and course of lower limb disease activity and walking disability over the first 5 years of juvenile idiopathic arthritis: results from the childhood arthritis prospective studyGordon J Hendry, Stephanie J Shoop-Worrall, Jody L Riskowski, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Pharmacogenomics|May 17, 2016
Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohortSamantha Louise Smith, Darren Plant, Xiu Hue Lee, et al.
Rheumatology (Oxford, England)|January 17, 2019
Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry dataSamuel Hawley, M Sanni Ali, René Cordtz, et al.
Pharmacogenetics and Genomics|March 20, 2010
Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment responseCatherine Potter, Laura J Gibbons, John D Bowes, et al.
Journal of Pediatric Psychology|April 23, 2025
The interplay between pain and disease activity: personal models of pain beliefs and emotional representations in children and young people with juvenile idiopathic arthritis in a UK nationwide prospective inception cohortDanielle C Mountain, Stephanie Shoop-Worrall, Lis Cordingley, et al.
Pharmacogenetics and Genomics|March 6, 2009
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patientsJohn D Bowes, Catherine Potter, Laura J Gibbons, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
The Pharmacogenomics Journal|September 1, 2018
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisJonathan Massey, Darren Plant, Kimme Hyrich, et al.
Rheumatology Advances in Practice|January 5, 2026
Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDsMichael Stadler, Shae Bindra, Annie Cheung, et al.
Rheumatology (Oxford, England)|June 30, 2020
Translating research into clinical practice: quality improvement to halve non-adherence to methotrexateAnne Barton, Meghna Jani, Christine Bundy, et al.
Rheumatology Advances in Practice|January 11, 2019
Prevalence and course of lower limb disease activity and walking disability over the first 5 years of juvenile idiopathic arthritis: results from the childhood arthritis prospective studyGordon J Hendry, Stephanie J Shoop-Worrall, Jody L Riskowski, et al.
Pageof 5